Focusing on the Apolipoprotein B mRNA editing enzyme, catalytic polypeptide (APOBEC) mutational signature (SBS2 and SBS13), a known adverse risk factor in MM, no significant differences in PFS were observed between APOBEC-positive and -negative samples (p = 0.47). This evidence concerns the gene APOB and Miyoshi myopathy.